Compare · CYTK vs JNJ
CYTK vs JNJ
Side-by-side comparison of Cytokinetics Incorporated (CYTK) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYTK and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 61.1x CYTK ($9.98B).
- Over the past year, CYTK is up 115.2% and JNJ is up 54.6% - CYTK leads by 60.7 points.
- CYTK has been more active in the news (18 items in the past 4 weeks vs 10 for JNJ).
- Both have 25 recent analyst ratings on file.
- Company
- Cytokinetics Incorporated
- Johnson & Johnson
- Price
- $80.15-0.23%
- $253.01+1.39%
- Market cap
- $9.98B
- $609.12B
- 1M return
- +6.61%
- +7.55%
- 1Y return
- +115.23%
- +54.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 18
- 10
- Recent ratings
- 25
- 25
Cytokinetics Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CYTK
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Wysenski Nancy was granted 75 shares, increasing direct ownership by 0.22% to 33,992 units (SEC Form 4)
- Director Wierenga Wendell was granted 75 shares, increasing direct ownership by 0.21% to 35,563 units (SEC Form 4)
- Director Kaye Edward M. Md was granted 151 shares, increasing direct ownership by 1% to 10,434 units (SEC Form 4)
- Director Henderson John T was granted 272 shares, increasing direct ownership by 0.35% to 78,360 units (SEC Form 4)
- Director Harrington Robert Arthur was granted 151 shares, increasing direct ownership by 0.69% to 21,932 units (SEC Form 4)
- Director Daly James M was granted 151 shares, increasing direct ownership by 5% to 3,390 units (SEC Form 4)
- President & CEO Blum Robert I sold $615,150 worth of shares (7,500 units at $82.02) and exercised 7,490 shares at a strike of $10.60, decreasing direct ownership by 0.00% to 377,820 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics Incorporated
- EVP Research & Development Malik Fady Ibraham exercised 3,500 shares at a strike of $7.80 and sold $303,170 worth of shares (3,500 units at $86.62) (SEC Form 4)
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson